AbCellera IPO Presentation Deck
INVESTOR HIGHLIGHTS
TECHNOLOGY IS THE SUREST
PATH TO A BETTER FUTURE.
We believe the new frontier of technology lies at the
interface of computation, engineering and biology.
Triple-digit CAGR, profitable,
cashflow positive²
1.19 2019
Centralized business model for
$140B¹ antibody-based
therapeutics market
Full-stack Al-powered antibody
discovery engine
AbCellera
174 employees³;
founded in 2012
94 antibody
discovery projects³
AbCellera-discovered COVID-19
antibody authorized for
emergency use in the
US & Canada
BACKED BY LEADING HEALTHCARE &
TECHNOLOGY INVESTORS TO SOLVE BIOLOGICS
DISCOVERY & DEVELOPMENT INCLUDING:
OrbiMed DCVC Bio Viking Global Investors. Peter Thiel
. Founders Fund Eli Lilly and Company
University of Minnesota Presight CapitalView entire presentation